The latest installment in BioPharma Dive’s data visualization series features a look at the emerging popularity of RNAi ...

A combination of the shot and the immunotherapy Keytruda cut the risk of relapse or death by 42% in a landmark melanoma study that met Wall Street expectations but triggered a “sell-the-news reaction, ...

Following exits for its subsidiaries Electra Therapeutics and Vega Therapeutics, Star is now mining for a new drug prospect.

Funds from the upsized offering will support a trio of protein-degrading medicines in development for allergic conditions as well as the autoimmune disorder Graves’ disease.

Shortly after winning a clearance in the skin disease dermatomyositis, brepocitinib posted results suggesting it might also ...

U.S. regulators have accepted a new submission for Vyglxia, offering the chance at a turnaround for another rare disease ...

Hibsago is viewed as a potential “functional cure” for chronic infections and an important part of the British drugmaker’s ...

Lower-than-expected sales of Xolair stood out as the Swiss drugmaker readies for an onslaught of generic competition for top products.

A rare disease drug previously spurned by the Food and Drug Administration will get another shot at approval after positive Phase 3 results that sent shares of its developer, Disc Medicine, soaring by ...

The launch prices of two-thirds of the new prescription drugs reviewed by the watchdog group ICER between 2022 and 2025 far exceeded the organization’s threshold of cost-effectiveness, according to a ...